

Adherium Confirms Clearance to Market in Canada for Flagship Products

Melbourne, Australia, 15 March 2016: Adherium Limited (ASX: ADR), a global leader in digital health technologies which address sub-optimal medication use in chronic disease; today announced that it has received final clearance to market in Canada for its SmartTurbo and SmartTouch devices. The SmartTurbo product works with AstraZeneca’s Symbicort® Turbuhaler, and the SmartTouch device with a range of pressurised metered dose inhalers supplied by a number of pharmaceutical companies, including GSK and Chiesi.

Adherium Group CEO, Garth Sutherland, said, “We are committed to ensuring our devices, which are proven to significantly improve the quality of life for people with respiratory diseases, are able to be supplied into all the major markets of the world. This clearance to market allows us to add Canada to the international markets which we already supply, including the US, Europe, China, Australia and New Zealand.”

****Ends****

ABOUT ADHERIUM

Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.

Adherium is a provider of digital health solutions to pharmaceutical, remote patient monitoring and clinical trials companies and organisations. The Company’s proprietary SmartInhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.

Clinical outcomes data has proven that the SmartInhaler platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults. In addition, interim data from a study at the University of Sheffield demonstrated a 144% increase in adherence, a restoration of lung function to 100% and a 37% reduction in oral steroids indicating reduced severe exacerbations in children. Both children and adults benefit from improved quality-of-life as a result of their improved adherence, demonstrating a substantial gain over current best practice treatment.

The SmartInhaler™ platform has so far been used in 63 projects (clinical, device validation or other) and has been referenced in 33 peer reviewed journal articles. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.

www.smartinhale.com | www.adherium.com

Enquiries:

At Adherium	Media enquiries	
Bronwyn Le Grice Head of Commercial Development & Corporate Affairs M +61 (0)424 862 600 E: bronwynlg@adherium.com	EU Media Sue Charles/Rozi Morris Instinctif Partners D +44 (0)20 7866 7860 E: adherium@instinctif.com	US Media Brian Baxter Lazar Partners D: +1 646 871 8491 E: bbaxter@lazarpartners.com
	AU/NZ Media Rudi Michelson Monsoon Communications D: +61 (0)3 9620 3333 E: rudim@monsoon.com.au	

For personal use only